Curis opens 11 CLL trial sites, stockholders approve reverse split
Tweet Send to a Friend
Curis, Inc. (NASDAQ: CRIS) announced that eleven clinical sites are now open for patient enrollment in its Phase 2 TakeAim ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
